Assembly Bio Q2 FY26 net loss narrows to $3.86 million; revenue rises to $13.37 million
ASMB•Pipeline plans
- Pipeline plans include ABI-6250 Phase 2 starts in chronic HDV by year-end 2026 and in PBC/PSC in Q1 2027; Gilead targets GS-1179 Phase 2 by end-2026.
Quarterly results
- Assembly Biosciences posted a GAAP net loss attributable to common stockholders of USD 3.9 million, or USD 0.20 a share, in Q2 2026.
- Revenue rose 39.01% year over year to USD 13.4 million, including a USD 5.1 million cumulative catch-up adjustment.
- Research and development expenses fell 7.51% to USD 14.9 million; general and administrative costs increased 4.51% to USD 4.8 million.
- Cash, cash equivalents and marketable securities climbed to USD 320.4 million at June 30, extending projected runway into 2029.
